Syndax Pharmaceuticals (NASDAQ: SNDX) — Company Overview, News & Financial Data
Syndax Pharmaceuticals focuses on developing cancer therapies, emphasizing epigenetics and immune-oncology.
Syndax Pharmaceuticals
Syndax Pharmaceuticals (NASDAQ:SNDX) is focused on developing therapies that could potentially provide significant improvements in the lives of cancer patients. Its operations span various stages of clinical development, with projects targeting a broad range of cancer types. Syndax is especially known for its work on epigenetics and immune-oncology, areas where they seek to unlock new treatment pathways. The main objectives of the company include advancing its clinical programs to commercialization, expanding its pipeline through strategic collaborations and research & development, and ultimately improving patient outcomes in the oncology field.
Snapshot
Operations
Products and/or services of Syndax Pharmaceuticals
- Axatilimab, a treatment targeting chronic graft versus host disease, after stem cell transplantation.
- Revumenib, designed for acute myeloid leukemia and myelodysplastic syndrome, targets leukemia stem cells.
- SNDX-5613, a potent inhibitor of menin-MLL binding useful in leukemias with rearrangements in the MLL gene.
- SNDX-6352, a monoclonal antibody being investigated for its potential in a variety of fibrotic diseases.
- Entinostat, an oral small molecule targeting HDAC enzymes for breast cancer and non-small cell lung cancer, optimizing immune checkpoint therapy efficacy.
- Partnerships for developing immuno-oncology therapies, emphasizing combination treatments to enhance effectiveness in cancer treatment.
Syndax Pharmaceuticals executive team
- Michael A. MetzgerCEO & Director
- Keith Alan GoldanCFO, Treasurer & Principal Accounting Officer
- Luke J. AlbrechtGeneral Counsel & Corporate Secretary
- Steven ClosterChief Commercial Officer
- Nicholas A.J. BotwoodHead of Research & Development and Chief Medical Officer
- Peter OrdentlichCo-Founder & Chief Scientific Officer
- Richard A. HeymanCo-Founder
- Michael DownesCo-Founder
- Sharon KlahreVice President of Investor Relations & Communications
- Averi PriceSenior VP of Legal & Chief Compliance Officer
Latest news about Syndax Pharmaceuticals
Key financials
Reported results for Syndax Pharmaceuticals, in USD.
- Market cap
- 1.3B
- Revenue (TTM)
- 289.7M
- P/E ratio
- —
- EPS (diluted, TTM)
- -2.4
- Dividend yield
- —
- Profit margin
- -72.3%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 172.4M | -273.1M | -285.4M | |
| 23.7M | -339.7M | -318.8M | |
| 0 | -230M | -209.4M | |
| 126.6M | -151.8M | -143.7M |